J Neurol Surg B Skull Base 2022; 83(S 01): S1-S270
DOI: 10.1055/s-0042-1743834
Presentation Abstracts
Podium Abstracts

Metabolic Syndrome and 30-Day Outcomes Following Resection of Benign Cranial Nerve Neoplasms

Rushi Patel
1   Rutgers New Jersey Medical School, Newark, New Jersey, United States
,
Kathryn Bregna
2   Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, United States
,
Esther Ogbuokiri
2   Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, United States
,
Ariel Omiunu
2   Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, United States
,
Prayag Patel
2   Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, United States
,
Christina H. Fang
3   Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center, New York City, New York, United States
,
Jordon G. Grube
4   Division of Otolaryngology/Head and Neck Surgery, Department of Surgery, Albany Medical Center, Albany, New York, United States
,
Jean Anderson Eloy
2   Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, United States
› Author Affiliations
› Further Information
Also available at
 

Introduction: Metabolic syndrome (MetS) is a complex disorder characterized by the presence of numerous comorbidities, including hypertension, diabetes mellitus (DM), and obesity. In prior studies, MetS has demonstrated a negative impact on functional recovery following various surgical procedures. The present study aims to examine the effects of MetS on 30-day outcomes in patients undergoing benign cranial nerve tumor (BCNT) resection.

Methods: The 2005 to 2018 American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database was queried for all patients with an International Classification of Diseases, 10th edition, Clinical Modification (ICD-10-CM) diagnosis code of D33.3, BCNT. MetS was defined as having DM, hypertension, and a body mass index >30 kg/m2, using pre-set criteria from prior NSQIP studies. Univariate (e.g., chi-square, unpaired t-tests) and multivariate logistic regression analyses were performed to evaluate postoperative outcomes.

Results: A total of 1,248 patients who underwent BCNT were identified. Overall mean BMI was 29.0 ± 7.0 kg/m2. 38.1% of BCNT patients were obese, of which 49 (12.9%) had metabolic syndrome. Patients with MetS were more likely to be ASA class III or IV (p < 0.001) and more likely to have a history of congestive heart failure (CHF) (p = 0.001). Patients with MetS also demonstrated higher rates of postoperative medical complications, including myocardial infarction (p = 0.001), deep vein thrombosis (DVT) (p = 0.005), and renal insufficiency (p = 0.001). In addition, MetS patients had a longer length of stay following BCNT (9.8 ± 14.7 days vs 4.7 ± 8.0 days, p < 0.001). On multivariate regression analysis, patients with MetS had a significantly greater risk for postoperative MI (odds ratio [OR]=33.928, p = 0.030) and DVT (OR=4.002, p = 0.046) compared with nonmetabolic patients.

Conclusion: MetS was found to be independently associated with an increased risk of MI and DVT in patients undergoing resection of benign cranial nerve tumors. These findings may present avenues for optimization of comorbidities prior to BCNT and may improve strategies for postoperative management.



Publication History

Article published online:
15 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany